GHRP-2
Also known as: Pralmorelin, Growth Hormone-Releasing Peptide-2, GPA 748, KP-102 D, KP-102 LN, KP-102D, KP-102LN, D-Ala-D-(β-naphthyl)-Ala-Ala-Trp-D-Phe-Lys-NH2
Growth Hormone Secretagogue (GHS) / Synthetic Growth Hormone-Releasing Peptide (GHRP); Ghrelin Receptor (GHS-R1a) Agonist
What it is
GHRP-2 is a peptide used to stimulate growth hormone release, both for diagnostic testing of GH deficiency and, off-label, for body composition and recovery. It works by activating the same receptor as ghrelin, the body's natural hunger and GH-signaling peptide. Not FDA-approved for therapeutic use; banned by WADA.
The scientific side
GHRP-2 is a synthetic hexapeptide (D-Ala-D-β-naphthyl-Ala-Ala-Trp-D-Phe-Lys-NH2) that acts as a potent agonist at the GHS-R1a (ghrelin) receptor, which is present at both the pituitary and hypothalamic levels (PMID 9465289, PMID 26551992). GHRP-2 stimulates GH secretion through a receptor and intracellular signaling pathway distinct from that of GHRH: in human acromegalic somatotrophs, GHRP-2 increases GH secretion mainly via the protein kinase C (PKC) pathway and does not act through the GHRH/GRF receptor (PMID 9688350, PMID 9798733). GHRP-2 also stimulates ACTH, cortisol, and prolactin secretion (PMID 9285939, PMID 10195374). Its GH-releasing activity is synergistic with GHRH (PMID 9465289, PMID 9186261). GHRP-2 binds to CD36, a scavenger receptor for oxidized LDL, and may suppress vascular oxidative stress independently of GH. It also attenuates PKC-mediated inflammatory signaling in granulosa cells via inhibition of p38, JNK, and NF-κB pathways. GH secretion induced by GHRP-2 is subject to negative feedback inhibition by somatostatin.
Class: Growth Hormone Secretagogue (GHS) / Synthetic Growth Hormone-Releasing Peptide (GHRP); Ghrelin Receptor (GHS-R1a) Agonist
Administration & storage
- Administration
- Intravenous bolus (PMID: 17609397PMID: 20662346PMID: 9543135PMID: 33197153PMID: 21249726PMID: 19907099)Intravenous continuous infusion (PMID: 10037246PMID: 12030918PMID: 10946861PMID: 15699539)Subcutaneous infusion (PMID: 15699539)Subcutaneous injection twice daily (PMID: 19819949 — animal study)Intranasal administration (PMID: 9390009PMID: 25869809)Oral administration (PMID: 21298258PMID: 12932743)
- Storage
- One abstract confirmed long-term stability of GHRP-2 in dried blood spot (DBS) samples for >2 years. No storage conditions for prepared solutions or lyophilized powder are described in the reviewed abstracts.
- Cautions
- GHRP-2 stimulates ACTH and cortisol secretion in addition to GH; this may confound interpretation of HPA-axis tests and represents an off-target endocrine effect (PMID: 9285939, PMID: 20431231).,GHRP-2 stimulates prolactin release; magnitude is lower than TRH but comparable across doses studied (PMID: 9285939, PMID: 10195374).,GHRP-2 can mask rhGH doping detection by increasing both recombinant and pituitary GH isoforms, altering the Rec/Pit ratio used in isoform immunoassay.,Black-market products labeled as GHRP-2 or related peptides may be mislabeled, adulterated, or contain novel analogues (e.g., Gly-GHRP-2) of unknown activity and safety (PMID: 29864719, PMID: 30051972).,No long-term human safety data are available from these abstracts; cancer incidence, mitogenic risk, and long-term metabolic consequences have not been established in rigorous controlled trials.,Sterile technique and appropriate clinical oversight are required for any injectable administration.
Legal & regulatory status
Not stated in reviewed literature as currently FDA-approved. One abstract notes Wyeth (formerly American Home Products) discontinued US development for GH deficiency. WADA-prohibited for use in sport. Requires manual…
Listed on the WADA Prohibited List as a prohibited substance in sport (PMID: 20552695, PMID: 20431231, PMID: 25869809)
Not stated in reviewed literature — requires manual verification. Kaken sublicensed to Wyeth for US and Canada per PMID: 15230633; no approval stated.
What it's studied for
- Provocative test for diagnosis of adult growth hormone deficiency (GHD) Human observational
- In 77 healthy subjects and 58 GHD patients, 100 µg IV GHRP-2 showed favorable reproducibility. Cut-off for GHD diagnosis: 15 µg/L peak GH (equivalent to 9 µg/L when calibrated to WHO 98/574 standard). GH response mildly influenced by age and adiposity. PMID 17609397 Chihara et al., European Journal of Endocrinology (2007)
- GHRP-2 test compared to ITT and arginine test in 71 Japanese adults with pituitary tumors. GHRP-2 yielded higher peak GH (median 28.88 µg/L) than ITT. Sensitivity 81.3%, specificity 94.5% for severe AGHD vs. ITT. PMID 23079545 Kinoshita et al., Endocrine Journal (2013)
- In Japan, GHRP-2 test recommended as convenient and safe GH stimulation test. Cut-off for severe AGHD: peak GH ≤9 µg/L. GH replacement initiated at 3 µg/kg body weight/day with dose titration. PMID 25070016 Fukuda et al., Neurologia medico-chirurgica (2014)
- In 56 children with growth disorders, 2 µg/kg IV GHRP-2 showed favorable correlation with ITT. Sensitivity-specificity crossover at 15 µg/L. Test completed in one hour or less; considered safe. PMID 20662346 Asakura et al., Journal of Pediatric Endocrinology & Metabolism (2010)
- In 23 adolescents, robust GH responses observed in idiopathic GHD (median 88.9 ng/mL) and short stature (median 90.1 ng/mL) groups, suggesting current cut-offs may miss some GHD patients in adolescents. PMID 38958228 Onuki et al., Journal of Pediatric Endocrinology & Metabolism (2024)
- Assessment of anterior pituitary reserve and adrenocortical function in pituitary disease Human observational
- In 65 elderly patients (≥65 yr) with non-functioning pituitary neuroendocrine tumors, GH response to GHRP-2 correlated significantly with adrenocortical function. Optimal cut-off for correlating adrenocortical function with GH response: 8.08 ng/mL (specificity 0.868, sensitivity 0.852). PMID 37295337 Teramoto et al., Growth Hormone & IGF Research (2023)
- GHRP-2 test evaluated for HPA axis failure in 47 patients. Cut-off of 11.6 µg/dL for peak serum cortisol predicted secondary hypoadrenalism with 88.9% specificity and 89.7% sensitivity. IV bolus of 100 µg GHRP-2 administered. PMID 27020037 Arimura et al., Endocrine Journal (2016)
- In 6 patients with hypothalamo-pituitary disorders, GHRP-2 stimulated significant ACTH release, suggesting direct pituitary ACTH stimulatory activity. PMID 20431231 Kimura et al., Endocrine Journal (2010)
- Evaluation of GH secretion in patients with non-functioning pituitary adenomas (NFPA/NFPT) Human observational
- In 76 NFPA patients, preoperative GHRP-2 peak GH reflected severity of hypopituitarism and predicted postoperative GH recovery. Cut-off for severe AGHD: peak GH ≤9 ng/mL. PMID 31776295 Soga et al., Endocrine Journal (2020)
- Among 104 NFPA/Rathke's cyst patients, 43% had severe GHD by GHRP-2 test. BMI, free thyroxine, and tumor height were significant predictors. Overweight associated with severe GHD (OR 3.86). PMID 35452483 Seki & Ichihara, PLoS One (2022)
- Reactivation of GH secretion in prolonged critical illness Human RCT
- Continuous IV GHRP-2 infusion (1 µg/kg/h) synchronized GH, TSH, and prolactin release in prolonged critical illness. GHRH alone could not achieve the same effect. PMID 10037246 Van den Berghe et al., European Journal of Endocrinology (1999)
- In 33 critically ill men, GHRP-2 (1 µg/kg/h IV) reactivated GH secretion and normalized IGF-I, IGFBP-3, and ALS. Combined GHRP-2 + TRH + GnRH produced superior endocrine and metabolic effects. PMID 12030918 Van den Berghe et al., Clinical Endocrinology (2002)
- Stimulation of food intake / appetite Human observational
- In 7 lean healthy men, subcutaneous infusion of GHRP-2 (1 µg/kg/h for 270 min) increased ad libitum food intake by 35.9 ± 10.9% vs. saline. All subjects increased intake. PMID 15699539 Laferrère et al., Journal of Clinical Endocrinology & Metabolism (2005)
- In 10 GH-deficient children, oral GHRP-2 (900 µg/kg b.i.d. for 12 months) produced transient appetite stimulation in 7/10 patients during first 6 months; BMI SDS did not change significantly. PMID 12932743 Mericq et al., Journal of Pediatric Endocrinology & Metabolism (2003)
- Treatment of short stature in children (investigational) Human observational
- In 15 short-stature children, intranasal GHRP-2 (5–15 µg/kg twice then three times daily for up to 24 months) increased height velocity from 3.7 to 6.1 cm/year at 6 months. Well tolerated. PMID 9390009 Pihoker et al., Journal of Endocrinology (1997)
- Modulation of pulsatile GH secretion (neuroendocrine studies in healthy adults) Human RCT
- In 26 older men (randomized, double-blind, placebo-controlled), continuous GHRP-2 infusion combined with GHRH pulses modulated pulsatile GH secretion; testosterone, estradiol, and BMI were independent modulators. PMID 23485864 Norman et al., American Journal of Physiology (2013)
- In 10 healthy men, SSTR-2/-5 agonism (octreotide) suppressed GHRP-2-stimulated GH burst mass, frequency, and irregularity, demonstrating somatostatin-GHRP-2 interaction. PMID 15356066 Iranmanesh et al., Journal of Clinical Endocrinology & Metabolism (2004)
- Anti-inflammatory and antioxidant effects (in vitro and animal models) Mixed
- In KGN human ovarian granulosa cells (in vitro), GHRP-2 attenuated PKC-induced COX-2 and IL-8 expression, prostaglandin E2 secretion, and inflammatory signaling via p38, JNK, and NF-κB pathways. PMID 27548147 Chao et al., International Journal of Molecular Sciences (2016)
- In ApoE-/- mice, GHRP-2 (20 µg twice daily sc for 12 weeks) suppressed aortic superoxide production and decreased interferon-γ but did not reduce atherosclerotic plaque area. PMID 19819949 Titterington et al., Endocrinology (2009)
- Promotion of growth performance in animals with growth retardation Animal studies only
- In growth-retarded yaks, GHRP-2 injection significantly enhanced ADG, myofiber diameter, serum GH and IGF-1 levels, and upregulated GHR, IGF-1, and PI3K/Akt/mTOR pathway expression in liver and skeletal muscle. PMID 26894743 Hu et al., PLoS One (2016)
- Potential role in cachexia treatment Human observational
- Narrative review identifies GHRP-2 as a potential agent in wasting syndrome treatment; notes evidence-based recommendations are not available for some uses. PMID 35758863 Celichowska et al., Journal of Pain & Palliative Care Pharmacotherapy (2022)
- Diagnosis of TSH-producing pituitary adenomas Human observational
- In 5 patients with TSH-producing adenomas, 2/5 (40%) showed >50% TSH increase above baseline in the GHRP-2 test; proposed as a potential additional diagnostic tool. PMID 29973439 Kageyama et al., Endocrine Journal (2018)
Safety signals
- Elevated ACTH and cortisol secretion following GHRP-2 administration in healthy subjects and patients; ACTH/cortisol-releasing activity comparable to hCRH PMID 9285939
- Prolactin release stimulated by GHRP-2 in humans (PRL-releasing activity lower than TRH but significant) PMID 10195374
- Increased food intake (35.9% above saline) observed in healthy men during GHRP-2 infusion, raising concern for appetite dysregulation PMID 15699539
- Transient appetite stimulation reported in 7/10 GH-deficient children during first 6 months of oral GHRP-2 at 900 µg/kg b.i.d. PMID 12932743
- GH secretagogues as a class associated with some concern for decreases in insulin sensitivity / increases in blood glucose PMID 28400207
- On day 5 of critical illness treatment, serum lactate levels and WBC count were increased by GHRP-2 infused alone and in combination with TRH (but not when GnRH was also added) PMID 12030918
- GHRP-2 administration can alter the GH isoform ratio used in anti-doping immunoassay, potentially masking concurrent rhGH doping PMID 21249726
- Reported adverse effects of GHS class (including GHRP-2) in self-administration context span prolactin and cortisol elevations, appetite changes, dysglycaemia, fluid retention, myalgia/arthralgia, and injection-site reactions PMID 42395176
Contraindications
- The insulin tolerance test (ITT) — the comparator standard for GHD diagnosis — is contraindicated in some patients (e.g., seizure history, cardiovascular disease); GHRP-2 test is positioned partly as a safer alternative for such populations including the elderly PMID 37295337
- No specific absolute contraindications to GHRP-2 are enumerated in the reviewed abstracts. Use in the context of unregulated self-administration is described as carrying uncertainty around product composition, dose, and safety PMID 42395176
Protocol
100 mcg subcutaneous injection, 3x daily (upon waking, pre-workout, and pre-sleep). Cycle: 8-12 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Intravenous bolus | 100 µg IV (single bolus, overnight fasting) | Single administration (blood sampling over 2 h) | human | Research PMID 17609397 |
| Intravenous | 100 µg IV (single bolus) | Single administration | human | Research PMID 27020037 |
| Intravenous bolus | 2 µg/kg IV (single bolus) | Single administration (blood sampling over 1 h) | human | Research PMID 20662346 |
| Intravenous bolus | 1 µg/kg IV over 1 min (single dose) | Single administration (blood sampling over 2 h) | human | Research PMID 54 (9543135) |
| Intravenous bolus | 1 µg/kg IV | Single administration | human | Research PMID 9543135 |
| Subcutaneous infusion | 1 µg/kg/h subcutaneous infusion for 270 minutes | 270 minutes (single session) | human | Research PMID 15699539 |
| Intravenous continuous infusion | 1 µg/kg/h continuous IV infusion | 5 days | human | Research PMID 10037246 |
| Intravenous continuous infusion | 1 µg/kg/h continuous IV infusion | 5 days | human | Research PMID 12030918 |
| Intravenous continuous infusion | 1 µg/kg/h continuous IV infusion | 24 hours | human | Research PMID 10946861 |
| Intranasal | 5–15 µg/kg intranasal, twice daily then three times daily | 6–24 months | human | Research PMID 9390009 |
| Intravenous bolus | 1 µg/kg IV bolus (acute testing dose) | Single administration | human | Research PMID 9390009 |
| Intravenous | 100 µg IV (single dose, administration study) | Single administration; DBS collected up to 4 h after injection | human | Research PMID 33197153 |
| Intravenous | 100 µg IV | Single administration | human | Research PMID 21249726 |
| Oral | 10 mg oral (single administration, excretion study) | Single administration; urine metabolite detected over 20 h | human | Research PMID 21298258 |
| Oral | 900 µg/kg orally twice daily | 12 months | human | Research PMID 12932743 |
| Intravenous bolus | 1 µg/kg IV and 2 µg/kg IV | Single administration | human | Research PMID 9285939 |
| Intravenous bolus | 2.0 µg/kg IV | Single administration | human | Research PMID 10195374 |
| Intravenous bolus | 1 µg/kg IV bolus | Single administration (within 3-h session) | human | Research PMID 15356066 |
| Intravenous bolus | 1 µg/kg IV bolus | Single session | human | Research PMID 11004017 |
| Subcutaneous | 20 µg twice daily subcutaneous | 12 weeks | animal | Research PMID 19819949 |
| Injection (route not further specified in abstract) | Not explicitly stated per-dose (GHRP-2 injection group) | Study period not explicitly stated in abstract | animal | Research PMID 26894743 |
| Intravenous and subcutaneous (both mentioned) | Not explicitly stated per-dose | 7–30 days (chronic administration) | human | Research PMID 8887169 |
| Intravenous bolus | 100 µg IV bolus | Single administration; measurements at 15, 30, 45, 60 min | human | Research PMID 19907099 |
| subcutaneous injection | 100 mcg | 3x daily (upon waking, pre-workout or midday, and pre-sleep) · 8-12 weeks | male biohackers and bodybuilders seeking GH pulse amplification | [Community] |
| subcutaneous injection | 200 mcg | 3x daily (upon waking, pre-workout or midday, and pre-sleep) · 8-12 weeks | experienced male bodybuilders and biohackers chasing stronger GH pulses | [Community] |
| subcutaneous injection | 100 mcg | 1x daily (pre-sleep) · 12-16 weeks | biohackers and anti-aging users seeking improved sleep quality and overnight recovery | [Community] |
| subcutaneous injection | 100 mcg | 2x daily (upon waking and pre-sleep) · 8-12 weeks | intermediate users wanting meaningful GH pulses with fewer injections than 3x/day | [Community] |
| subcutaneous injection | 100 mcg | 3x daily (upon waking, pre-workout, and pre-sleep) · 8-12 weeks | male and female biohackers running GHRP-2 combined with CJC-1295 no-DAC (Mod GRF 1-29) | [Community] |
| subcutaneous injection | 100 mcg | 3x daily (upon waking, pre-workout, and pre-sleep) · 8-12 weeks | biohackers stacking GHRP-2 with GHRP-6 to leverage complementary ghrelin receptor profiles | [Community] |
| subcutaneous injection | 25 mcg | 3x daily (upon waking, midday, and pre-sleep) · 8-12 weeks | female biohackers and smaller-framed individuals seeking GH benefits with minimized prolactin/cortisol side effects | [Community] |
| intranasal | 100 mcg | 2-3x daily · 4-8 weeks | biohackers avoiding injections seeking convenience, though noted as less effective than SubQ | [Community] |
| subcutaneous injection | 150 mcg | 3x daily (upon waking, pre-workout, and pre-sleep) · 8-12 weeks | male bodybuilders seeking a middle-ground dose between 100 mcg and 200 mcg per injection | [Community] |
| subcutaneous injection | 100 mcg | 1x daily (pre-workout) · 8-12 weeks | athletes and fitness-focused biohackers prioritizing performance and recovery over comprehensive GH optimization | [Community] |
All studies (42)
- PMID 10037246 Human RCT
Reactivation of GH secretion in prolonged critical illness - PMID 12030918 Human RCT
Reactivation of GH secretion in prolonged critical illness - PMID 15356066 Human RCT
Modulation of pulsatile GH secretion (neuroendocrine studies in healthy adults) - PMID 23485864 Human RCT
Modulation of pulsatile GH secretion (neuroendocrine studies in healthy adults) - PMID 9390009 Human observational
Treatment of short stature in children (investigational) - PMID 12932743 Human observational
Stimulation of food intake / appetite - PMID 15699539 Human observational
Stimulation of food intake / appetite - PMID 17609397 Human observational
Provocative test for diagnosis of adult growth hormone deficiency (GHD) - PMID 20431231 Human observational
Assessment of anterior pituitary reserve and adrenocortical function in pituitary disease - PMID 20662346 Human observational
Provocative test for diagnosis of adult growth hormone deficiency (GHD) - PMID 23079545 Human observational
Provocative test for diagnosis of adult growth hormone deficiency (GHD) - PMID 25070016 Human observational
Provocative test for diagnosis of adult growth hormone deficiency (GHD) - PMID 27020037 Human observational
Assessment of anterior pituitary reserve and adrenocortical function in pituitary disease - PMID 29973439 Human observational
Diagnosis of TSH-producing pituitary adenomas - PMID 31776295 Human observational
Evaluation of GH secretion in patients with non-functioning pituitary adenomas (NFPA/NFPT) - PMID 35452483 Human observational
Evaluation of GH secretion in patients with non-functioning pituitary adenomas (NFPA/NFPT) - PMID 35758863 Human observational
Potential role in cachexia treatment - PMID 37295337 Human observational
Assessment of anterior pituitary reserve and adrenocortical function in pituitary disease - PMID 38958228 Human observational
Provocative test for diagnosis of adult growth hormone deficiency (GHD) - PMID 19819949 Mixed
Anti-inflammatory and antioxidant effects (in vitro and animal models) - PMID 27548147 Mixed
Anti-inflammatory and antioxidant effects (in vitro and animal models) - PMID 8887169
Not explicitly stated per-dose Intravenous and subcutaneous (both mentioned) (human) - PMID 9186261
- PMID 9285939
1 µg/kg IV and 2 µg/kg IV Intravenous bolus (human) - PMID 9465289
- PMID 9543135
1 µg/kg IV Intravenous bolus (human) - PMID 9688350
- PMID 9798733
- PMID 10195374
2.0 µg/kg IV Intravenous bolus (human) - PMID 10946861
1 µg/kg/h continuous IV infusion Intravenous continuous infusion (human) - PMID 11004017
1 µg/kg IV bolus Intravenous bolus (human) - PMID 19907099
100 µg IV bolus Intravenous bolus (human) - PMID 21249726
100 µg IV Intravenous (human) - PMID 21298258
10 mg oral (single administration, excretion study) Oral (human) - PMID 25869809
Not specified (nasal administration, single volunteer) Intranasal (human) - PMID 26551992
- PMID 26894743 Animal studies only
Promotion of growth performance in animals with growth retardation - PMID 28400207
GH secretagogues as a class associated with some concern for decreases in insulin sensitivity / increases in blood glucose - PMID 29864719
- PMID 30051972
- PMID 33197153
100 µg IV (single dose, administration study) Intravenous (human) - PMID 42395176
Reported adverse effects of GHS class (including GHRP-2) in self-administration context span prolactin and cortisol elevations, appetite changes, dysglycaemia,